Stock Market Cafe
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Stock Market Cafe
No Result
View All Result
Home Trading News

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

by
December 6, 2022
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Meta set to report fourth-quarter earnings after the bell

Biden and McCarthy clash ahead of White House debt ceiling meeting

Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.
Dado Ruvic | Reuters

PfizerModerna

Pfizer asked a federal court in Massachusetts on Monday to dismiss Moderna’s lawsuit seeking monetary damages for alleged patent violations related to the Boston company’s Covid vaccine. Pfizer asked the court to stop Moderna from suing it or its partners again over three alleged patent infringements.

Moderna, in a complaint filed in August, accused Pfizer of copying two key pieces of technology that make the messenger RNA Covid vaccines possible.

Moderna accused Pfizer of using the same modification to mRNA that keeps the molecule stable long enough to program human cells to produce the crucial spike protein that triggers an immune response against Covid.

Moderna also accused Pfizer of using the same full-length spike protein in its Covid shots. Moderna says it demonstrated a full spike produced an immune response in 2015 when it developed an mRNA vaccine against the Middle East Respiratory Syndrome. That vaccine never went to market.

“The Moderna inventions that Pfizer and BioNTech chose to copy were foundational for the success of their vaccine,” the company claimed.

Pfizer and its German partner BioNTech vigorously rejected those allegations, saying the technological building blocks for the vaccines were developed by a field of research scientists before the pandemic began. They accused Moderna of trying to “place itself in the spotlight alone.”

“Moderna is wrong, and its revisionist history is not based on fact. Pfizer and BioNTech did not copy Moderna’s technology,” Pfizer said in its response. “Rather, Pfizer and BioNTech independently developed their vaccine by utilizing innovation from their respective scientists and relying upon decades of research conducted by others before the pandemic began.”

Pfizer said the modification to mRNA was developed by research scientists at the University of Pennsylvania, one of whom is now an executive at BioNTech. It rejected Moderna’s claim to own the full-length spike protein technology. Pfizer said scientists have worried about coronaviruses since the 2003 SARS outbreak and by 2009 scientists understood the full-length spike induced a strong immune response.

Pfizer and Moderna have generated tens of billions of dollars in revenue from the Covid vaccines and generated windfall profits since the shots were first authorized in December 2020.

Moderna is asking the court to award it monetary damages since March 2022 including royalties and lost profits with interest. The company is also seeking enhanced damages up to three times the amount of compensatory damages found.

CNBC Health & Science

Read CNBC’s latest global health coverage:

CDC encourages people to wear masks to help prevent spread of Covid, flu and RSV over the holidaysFDA pulls Covid antibody treatment because it’s not effective against dominant omicron variantsFauci says China has done a bad job vaccinating the elderly and their shots are not very effective against CovidCDC will test sewage for polio outside New York to see if it’s circulating elsewhere in nationDrug overdose deaths among seniors have more than tripled in two decadesTwitter stops policing Covid misinformation under CEO Elon MuskDr. Jha: The U.S. is ready to ‘move on’ from Covid if people ‘keep their immunity up to date’China’s Covid infections drop for the first time in more than a weekChina touts vaccination progress as it seeks reopening path; encourages booster shots for seniorsFlu hospitalizations increase nearly 30% as U.S. enters holiday seasonU.S. criticizes China’s zero Covid strategy, says Beijing needs to boost vaccination among elderlyOmicron BQ Covid variants that threaten people with compromised immune systems are now dominant in U.S.Mainland China’s total daily Covid cases soar above Shanghai lockdown highsMeasles poses growing threat to kids as vaccinations decline globally, CDC and WHO warnAbortion pill is the most common method to end a pregnancy in the U.S., CDC says

ShareTweetPin

Related Posts

Biden and McCarthy clash ahead of White House debt ceiling meeting

by
February 1, 2023
0

House Republican leader Kevin McCarthy speaks to reporters following a meeting with U.S. President Joe Biden and other congressional leaders...

Meta set to report fourth-quarter earnings after the bell

by
February 1, 2023
0

In this article META Follow your favorite stocksCREATE FREE ACCOUNT Mark Zuckerberg, chief executive officer of Meta Platforms Inc., left,...

FedEx is laying off 10% of its officers and directors amid cooling demand

by
February 1, 2023
0

In this article FDX Follow your favorite stocksCREATE FREE ACCOUNT Raj Subramaniam, FedEx Corporation, speaks at the U.S. Chamber of...

Electric truck maker Rivian to lay off 6% of its workforce as EV price war concerns grow

by
February 1, 2023
0

In this article RIVN Follow your favorite stocksCREATE FREE ACCOUNT Workers inspect a Rivian R1T electric vehicle (EV) pickup truck...

Stocks making the biggest moves midday: Peloton, AMD, Snap and more

by
February 1, 2023
0

In this article EATPTONEAMOSMGSYKMTCHSNAPAMDFL Follow your favorite stocksCREATE FREE ACCOUNT A sign hangs above the entrance of a Foot Locker...

Next Post

Update: Framing Lumber Prices Close to Pre-Pandemic Levels

CoinMarketCap News, Dec. 5: Top Democrat Faces Backlash over Tweet to SBF

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Crocs sees fourth-quarter sales up 42%, CEO Andrew Rees says 2021 was ‘exceptional year’

    0 shares
    Share 0 Tweet 0
  • Biden didn’t accept Putin’s ‘red lines’ on Ukraine – here’s what that means

    0 shares
    Share 0 Tweet 0
  • Buying a car from the factory sounds expensive, but it can actually save you money. Here’s how to do it.

    0 shares
    Share 0 Tweet 0
  • The states that won’t tax military retirement in 2022

    0 shares
    Share 0 Tweet 0
  • Roth TSP vs. Roth IRA: How Do They Compare?

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.stockmarket-cafe.com
No Result
View All Result
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.stockmarket-cafe.com